Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,694 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Postoperative Bladder Neck to Pubic Symphysis Ratio Predictive for De Novo Overactive Bladder after Robot-Assisted Radical Prostatectomy.
Matsuyama N, Naiki T, Hamamoto S, Sugiyama Y, Kubota Y, Hamakawa T, Etani T, Iwatsuki S, Taguchi K, Ota Y, Gonda M, Aoki M, Morikawa T, Kato T, Okada A, Yasui T. Matsuyama N, et al. Among authors: sugiyama y. Diagnostics (Basel). 2023 Oct 11;13(20):3173. doi: 10.3390/diagnostics13203173. Diagnostics (Basel). 2023. PMID: 37891994 Free PMC article.
Hemoglobin and neutrophil levels stratified according to International Metastatic Renal Cell Carcinoma Database Consortium risk predict the effectiveness of ipilimumab plus nivolumab in patients with advanced metastatic renal cell carcinoma.
Tomiyama N, Tasaki Y, Hamamoto S, Sugiyama Y, Naiki T, Etani T, Taguchi K, Matsuyama N, Sue Y, Mimura Y, Odagiri K, Noda Y, Aoki M, Moritoki Y, Nozaki S, Kurokawa S, Okada A, Kawai N, Furukawa-Hibi Y, Yasui T. Tomiyama N, et al. Among authors: sugiyama y. Int J Urol. 2023 Sep;30(9):754-761. doi: 10.1111/iju.15198. Epub 2023 May 7. Int J Urol. 2023. PMID: 37150513
Elevated eosinophils proportion as predictor of immune-related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma.
Tasaki Y, Hamamoto S, Sugiyama Y, Tomiyama N, Naiki T, Etani T, Taguchi K, Matsuyama N, Sue Y, Mimura Y, Kubota H, Noda Y, Aoki M, Moritoki Y, Nozaki S, Kurokawa S, Okada A, Kawai N, Yasui T, Kimura K. Tasaki Y, et al. Among authors: sugiyama y. Int J Urol. 2023 Oct;30(10):866-874. doi: 10.1111/iju.15220. Epub 2023 Jun 6. Int J Urol. 2023. PMID: 37278575
C-Reactive Protein Is a Potential Prognostic Marker in Patient with Advanced or Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multi-Center Retrospective Study.
Morikawa T, Naiki T, Sugiyama Y, Naiki-Ito A, Nagai T, Etani T, Iida K, Isobe T, Noda Y, Shimizu N, Aoki M, Gonda M, Banno R, Kubota H, Ando R, Umemoto Y, Kawai N, Yasui T. Morikawa T, et al. Among authors: sugiyama y. Cancers (Basel). 2024 Apr 28;16(9):1725. doi: 10.3390/cancers16091725. Cancers (Basel). 2024. PMID: 38730675 Free PMC article.
Efficacy and Safety of Immuno-Oncology Plus Tyrosine Kinase Inhibitors as Late-Line Combination Therapy for Patients with Advanced Renal Cell Carcinoma.
Hamamoto S, Tasaki Y, Morikawa T, Naiki T, Etani T, Taguchi K, Iwatsuki S, Unno R, Takeda T, Nagai T, Kawase K, Mimura Y, Sugiyama Y, Okada A, Furukawa-Hibi Y, Yasui T. Hamamoto S, et al. Among authors: sugiyama y. J Clin Med. 2024 Jun 7;13(12):3365. doi: 10.3390/jcm13123365. J Clin Med. 2024. PMID: 38929893 Free PMC article.
Consensus statement on chronic pain treatment in cancer survivors.
Mamiya K, Iida H, Iseki M, Yamaguch S, Yonekura H, Ueno H, Kosugi T, Sasara T, Takao Y, Takasusuki T, Hashiguchi S, Hirakawa N, Sugiyama Y, Yamada K, Yamamoto K. Mamiya K, et al. Among authors: sugiyama y. J Anesth. 2024 Dec 4. doi: 10.1007/s00540-024-03427-0. Online ahead of print. J Anesth. 2024. PMID: 39627504 Review.
2,694 results